- Conditions
- ADHD
- Interventions
- Amphetamine Extended Release (ER) Tablet 20 mg
- Drug
- Lead sponsor
- Tris Pharma, Inc.
- Industry
- Eligibility
- 18 Years to 25 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–15
of 15
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Abuse, Drug
- Interventions
- Cebranopadol- 600 ug, Cebranopadol- 800ug, Cebranopadol- 1000ug, Treatment A:, Treatment B, Treatment C, Qualification
- Drug
- Lead sponsor
- Tris Pharma, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Acute Pain
- Interventions
- Cebranopadol, Oxycodone IR, Placebo Only, Placebo
- Drug
- Lead sponsor
- Tris Pharma, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 10
- States / cities
- Sheffield, Alabama • Little Rock, Arkansas • Tampa, Florida + 7 more
- Conditions
- Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
- Interventions
- Cebranopadol (GRT6005) Low-Dose Range, Cebranopadol (GRT6005) High-Dose Range, Placebo, Oxycodone CR
- Drug
- Lead sponsor
- Tris Pharma, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 619 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 83
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 74 more
- Conditions
- Prolonged QTc Interval, Pharmacokinetic
- Interventions
- 100 μg cebranopadol, 200 μg cebranopadol, 400 μg cebranopadol, Placebo to cebranopadol encapsulated tablets, 400 mg Moxifloxacin, Placebo to moxifloxacin encapsulated tablets
- Drug
- Lead sponsor
- Tris Pharma, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 171 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- West Bend, Wisconsin
- Conditions
- Acute Pain
- Interventions
- Cebranopadol 400 ug, Cebranopadol 200 ug, Placebo
- Drug
- Lead sponsor
- Tris Pharma, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 279 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 4
- States / cities
- Little Rock, Arkansas • Miami, Florida • Bellaire, Texas + 1 more
- Conditions
- Chronic Pain, Diabetic Neuropathies, Diabetes Mellitus
- Interventions
- Cebranopadol 100 µg, Cebranopadol 300 µg, Cebranopadol 600 µg, Pregabalin, Matching Placebo
- Drug
- Lead sponsor
- Tris Pharma, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 699 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 15
- States / cities
- Mesa, Arizona • Garden Grove, California • Laguna Hills, California + 11 more
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Amphetamine Extended Release Suspension [Dyanavel]
- Drug
- Lead sponsor
- Tris Pharma, Inc.
- Industry
- Eligibility
- 4 Years to 5 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Maitland, Florida
- Conditions
- Post Operative Pain
- Interventions
- GRT6005, Morphine, Placebo
- Drug
- Lead sponsor
- Tris Pharma, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- ADHD
- Interventions
- methylphenidate HCl, Mixed amphetamine salts extended release
- Drug
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 7 Years to 11 Years
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Brookline, Massachusetts
- Conditions
- ADHD
- Interventions
- AMPH ER Tab 5, 10, 15 and 20 mg, AMPH ER Tab Matching Placebo 5, 10, 15 and 20 mg
- Drug
- Lead sponsor
- Tris Pharma, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 3
- States / cities
- Bradenton, Florida • Maitland, Florida • Las Vegas, Nevada
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- amphetamine extended-release oral suspension, 2.5 mg/mL, Placebo extended-release oral suspension
- Drug
- Lead sponsor
- Tris Pharma, Inc.
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
- Conditions
- Human Abuse Potential
- Interventions
- Oxycodone 40 mg, Tramadol 600 mg, Placebo, Cebranopadol 600 µg, Cebranopadol 1000 µg
- Drug
- Lead sponsor
- Tris Pharma, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Pharmacokinetic
- Interventions
- Cebranopadol 200 μg tablet
- Drug
- Lead sponsor
- Tris Pharma, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 2
- States / cities
- Miami, Florida • Orlando, Florida
- Conditions
- Attention Deficit Disorder With Hyperactivity
- Interventions
- TRI102, Placebo
- Drug · Other
- Lead sponsor
- Tris Pharma, Inc.
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 5
- States / cities
- Newport Beach, California • Las Vegas, Nevada • Durham, North Carolina + 2 more